Our study suggests that C + D therapy promotes the infiltration of CD4+ and CD8+ CTLs and elevates the ratio of CD8+ T cells to FOXP3+ Tregs, eliciting local anti-cancer immunity in TME and resulting in prolonged survival outcomes. This evidence concerns the gene CD8A and cancer.